Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2026 which are attached hereto as Exhibit 99.1.…
Filed Aug 5, 2026Accepted Aug 5, 2026, 4:06 PM EDTCIK 927653Accession 0000927653-26-000232
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2026 which are attached hereto as Exhibit 99.1.
The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.
